Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
King Charles shares cancer treatment update, says it's a 'personal blessing' - 2Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- 3Hitler's madcap mega-railway would have linked Berlin with India
- 4How one man's concern saved his brothers from heart disease
- 5Vote in favor of the wide open action that revives your brain and soul!
- Mojtaba Khamenei unconscious in Qom, not actually running Iran
- Farmers worry about rising cost of fertiliser
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Air Force made critical errors during October 7 massacre, investigator says
- Carry Nature Inside with These Staggering Plant Decisions
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- SUVs Known for Their Looks As opposed to Their Capacity
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- IDF says up to 90% of Iran’s weapons industry could be hit within days
